Mayne Pharma Group Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume5.47 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive MYX News and Ratings via Email

Sign-up to receive the latest news and ratings for Mayne Pharma Group and its competitors with MarketBeat's FREE daily newsletter.

About Mayne Pharma Group

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally. The company operates through four segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. It also offers oral drug delivery systems; and contract development and manufacturing services to third-party customers. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.27 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Mayne Pharma Group (ASX:MYX) Frequently Asked Questions

What stocks does MarketBeat like better than Mayne Pharma Group?

Wall Street analysts have given Mayne Pharma Group a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mayne Pharma Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Mayne Pharma Group's earnings last quarter?

Mayne Pharma Group Limited (ASX:MYX) released its earnings results on Friday, February, 22nd. The company reported $0.02 earnings per share (EPS) for the quarter.
View Mayne Pharma Group's earnings history

Who are Mayne Pharma Group's key executives?

Mayne Pharma Group's management team includes the following people:
  • Mr. Scott Anthony Richards, MD, CEO & Exec. Director (Age 57, Pay $1.47M)
  • Mr. Peter Paltoglou, Chief Financial Officer
  • Mr. Stefan J. Cross, Pres of International Operations (Age 48)
  • Ms. Lisa Pendlebury, VP of Investor Relations & Communications
  • Ms. Kate Rintoul, Exec. VP & Gen. Counsel
  • Dr. Andrew O. Herdman Ph.D., VP of Group HR
  • Mr. Brant Schofield, Exec. VP of Specialty Products Division (Age 55)
  • Mr. Daniel Moore, Exec. VP of Generics Products Division
  • Mr. Gerard G. Nahum M.D., Chief Medical Officer
  • Mr. Donald Pearl, Exec. VP of Women's Health

Who are some of Mayne Pharma Group's key competitors?

What other stocks do shareholders of Mayne Pharma Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mayne Pharma Group investors own include Sundance Energy (SNDE), Aurora Cannabis (ACB), Turquoise Hill Resources (TRQ), Telstra (TLS), The Green Organic Dutchman (TGODF), Perseus Mining (PRU), OrganiGram (OGI), Karoon Energy (KAR), Crown Resorts (CWN) and Cronos Group (CRON).

What is Mayne Pharma Group's stock symbol?

Mayne Pharma Group trades on the ASX under the ticker symbol "MYX."

How much money does Mayne Pharma Group make?

Mayne Pharma Group has a market capitalization of $0.00 and generates $400.78 million in revenue each year.

How many employees does Mayne Pharma Group have?

Mayne Pharma Group employs 780 workers across the globe.

What is Mayne Pharma Group's official website?

The official website for Mayne Pharma Group is

Where are Mayne Pharma Group's headquarters?

Mayne Pharma Group is headquartered at 1538 Main North Rd, ADELAIDE, SA 5106, Australia.

How can I contact Mayne Pharma Group?

Mayne Pharma Group's mailing address is 1538 Main North Rd, ADELAIDE, SA 5106, Australia. The company can be reached via phone at +61-8-82092666.

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.